BPC-157, short for Body Protection Compound-157, is a 15-amino-acid peptide
doi: 10.1371/journal.ppat.1002454
It has garnered significant attention for its potential in cognitive enhancement and the treatment of neurodegenerative diseases
A meta-analysis of 7,545 patients enrolled in 11 clinical studies showed that patients treated with Metalyse achieved significantly higher rates of functional independence, defined as a modified Rankin Scale score of 0-1 at three months, than those treated with Actilyse while maintaining a similar safety profile
The idea is appealing on its face: take the part of growth hormone responsible for burning fat, leave out the rest, and you have a clean, targeted lipolytic agent without growth-hormone side effects
The commonly used chemotherapeutic drug sorafenib is resistant to treatment in patients with advanced HCC